MannKind (MNKD) Reports Break-Even Earnings for Q2

Financial Performance - MannKind reported break-even quarterly earnings per share, missing the Zacks Consensus Estimate of $0.04, compared to earnings of $0.05 per share a year ago, representing an earnings surprise of -100.00% [1] - The company posted revenues of $76.53 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 2.58%, and this is an increase from year-ago revenues of $72.39 million [2] Market Performance - MannKind shares have lost about 38% since the beginning of the year, while the S&P 500 has gained 7.1% [3] - The current Zacks Rank for MannKind is 4 (Sell), indicating expected underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for the coming quarter is $0.04 on revenues of $81.32 million, and for the current fiscal year, it is $0.19 on revenues of $321.73 million [7] - The estimate revisions trend for MannKind was unfavorable ahead of the earnings release, which may impact future stock movements [5][6] Industry Context - MannKind belongs to the Medical - Biomedical and Genetics industry, which is currently in the bottom 42% of the Zacks industries, indicating potential challenges for stock performance [8] - Another company in the same industry, Phathom Pharmaceuticals, is expected to report a quarterly loss of $0.76 per share, with revenues projected to be $36.26 million, reflecting a year-over-year increase of 395.4% [9][10]